Metformin therapy to prohibit progression in patients with abdominal aortic aneurysm

Metformin therapy to prohibit progression in patients with abdominal aortic aneurysm - METAAA Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-001788-19-AT

Enrollment

170

Registered

2018-08-01

Start date

2018-08-24

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal aortic aneurysm

Interventions

Trade Name: SmPC Glucophage 500 mg - clean Product Name: SmPC Glucophage 500 mg - clean Product Code: Glucophage IR 500, SKU no FR2PM90 AUT Pharmaceutical Form: Tablet Pharmaceutical form of the place

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Infrarenal AAA of 3-4.9 cm maximum diameter Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 170 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 170

Exclusion criteria

Exclusion criteria: premenopausal female patients with a pregnancy possibility • patients with diabetes • indication for surgical AAA repair • life expectancy <2 years • contraindications for metformin, i.e. severly reduced kidney function (eGFR <30 ml/min), liver dysfunction, pancreatitis, alcohol abusus, malnutrition and decompensated heart failure

Design outcomes

Primary

Measure	Time frame
Main Objective: Metformin therapy to inhibit progression in patients with abdominal aortic aneurysma;Secondary Objective: subsets of neutrophils will be detected by immunostaining of surface markers (such as CD66b, CD16, CD62L and ICAM-1) platelet-surface marker (like CD41 Neutrophil and NET parameters such as citrullinated histone H3, oxidized mitochondrial DNA and elastase;Primary end point(s): AAA growth at 12 months in mm;Timepoint(s) of evaluation of this end point: 12 months	—

Measure

Time frame

Main Objective: Metformin therapy to inhibit progression in patients with abdominal aortic aneurysma;Secondary Objective: subsets of neutrophils will be detected by immunostaining of surface markers (such as CD66b, CD16, CD62L and ICAM-1) platelet-surface marker (like CD41 Neutrophil and NET parameters such as citrullinated histone H3, oxidized mitochondrial DNA and elastase;Primary end point(s): AAA growth at 12 months in mm;Timepoint(s) of evaluation of this end point: 12 months

—

Secondary

Measure	Time frame
Secondary end point(s): Neutrophil activation and NETs at 6 and 12 months;Timepoint(s) of evaluation of this end point: 6 and 12 months	—

Countries

Austria

Contacts

Public ContactChristoph Neumayer

Medical University Vienna

christoph.neumayer@meduniwien.ac.at+4304040069560

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026